2017 American Transplant Congress
Immunosuppression (IS) Withdrawal (ISW) After ATG and Rituximab in Kidney Transplant Recipients (KTR): RESTARRT Early Results (NCT01318915).
Growing evidence implicates B cells in transplant tolerance. RESTARRT is a 6-center ISW study in adult living-related-donor KTR receiving ATG induction and rituximab with a…2017 American Transplant Congress
Evaluating T Cell Repopulation Post Alemtuzumab Induction with a Belatacept-Based Regimen.
Department of Surgery, Duke University, Durham, NC
We reported that alemtuzumab induction followed by belatacept-sirolimus based immunosuppression effectively prevents costimulation blockade resistant rejection (CoBRR). This study investigates the phenotypic characteristics of repopulating…2017 American Transplant Congress
Alemtuzumab Induction and Belatacept Maintenance in Marginal Pathology Renal Allografts.
University of Maryland, Baltimore
Background: The potential for improved outcomes with CNI avoidance may be important for kidneys with an increased likelihood of impaired graft function. We performed a…2017 American Transplant Congress
Clinical and Pathologic Characteristics of Acute Rejection After Alemtuzumab Induction in Kidney Transplant Recipients.
Background: Alemtuzumab induction (AZI) can be used for early steroid withdrawal in kidney transplant (KTx) recipients. There is evidence that AZI-induced lymphocyte depletion leads to…2017 American Transplant Congress
The Outcome of 0 Mismatch Kidney in Pediatric Population with High Immunologic. The Impact of Induction Therapy. An Analysis of UNOS Database.
Surgery, State University New York, Syracuse, NY
Background: 0 mismatch kidneys have superior outcomes in primary transplant recipient. We performed Analysis UNOS database to determine the outcome of high PRA transplant pediatric…2016 American Transplant Congress
Clinical Factors That Determine the More Appropriate Induction Agent: ATG versus IL-2 Receptor Antagonists.
Antithymocyte globulin (ATG) is recommended over IL-2 receptor antagonist (IL2) in high-risk recipients for induction immunosuppression. However, “high-risk” status has not been defined in an…2016 American Transplant Congress
Induction Therapy in Low Risk African American Kidney Transplant Recipients: Donor Factors.
African Americans (AA) are at a higher risk of acute rejection and graft loss compared to non-AA kidney transplant (KT) recipients. Guidelines specify induction choices…2016 American Transplant Congress
Induction Immunosuppression and Post-Transplant Outcomes in Kidney Recipients with Hepatitis C Virus.
Kidney transplantation is a well-established treatment option for ESRD patients with Hepatitis C virus (HCV). However, the optimal induction regimen for this population is uncertain,…2016 American Transplant Congress
Evaluation of Dose Dependent Rabbit Anti-Thymocyte Globulin Induction in Risk-Stratified Kidney Transplant Recipients.
UC San Diego Health System, San Diego, CA.
Background: Rabbit anti-thymocyte globulin (rATG) is a depleting polyclonal antibody often used for induction following kidney transplantation to help prevent acute rejection. The optimal dosage…2016 American Transplant Congress
A Prospective Randomized Study to Evaluate the Efficacy and Safety of Rabbit Antithymocyte Globulin (rATG) 3mg/Kg vs. 6mg/Kg in Kidney Transplant Patients Under Minimization Maintenance Immunosuppressive Regimen.
Hospital Geral de Fortaleza, Fortaleza, Brazil.
Background: rATG dosed from 4.5 to 7.5mg/kg has been the standard of care in most transplant centers. Recent studies have demonstrated similar efficacy with doses…
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 31
- Next Page »